Aditya Birla Sun Life Pharma & Healthcare Fund Direct Growth

Fund Overview

Fund Size

₹950 Cr

Expense Ratio

0.86%

ISIN

INF209KB1O25

Minimum SIP

₹1,000

Exit Load

1.00%

Inception Date

11 Jul 2019

About this fund

Aditya Birla Sun Life Pharma & Healthcare Fund Direct Growth is a Sector - Healthcare mutual fund schemes offered by Aditya Birla SL Mutual Fund. This fund has been in existence for 6 years, 11 months and 2 days, having been launched on 11-Jul-19.
As of 12-Jun-26, it has a Net Asset Value (NAV) of ₹37.37, Assets Under Management (AUM) of 950.31 Crores, and an expense ratio of 0.86%.

Aditya Birla Sun Life Pharma & Healthcare Fund Direct Growth has given a CAGR return of 20.89% since inception.
The fund's asset allocation comprises around 96.83% in equities, 0.00% in debts, and 3.17% in cash & cash equivalents.
You can start investing in Aditya Birla Sun Life Pharma & Healthcare Fund Direct Growth with a SIP of ₹1000 or a Lumpsum investment of ₹1000.

Performance against Category Average

In this section, we compare the returns of the scheme with the category average over various periods. Periods for which the fund has outperformed its category average are marked in green, otherwise red.

1 Year

+12.09%

+9.02% (Cat Avg.)

3 Years

+25.34%

+23.88% (Cat Avg.)

5 Years

+13.99%

+13.21% (Cat Avg.)

Since Inception

+20.89%

— (Cat Avg.)

Portfolio Summaryas of 31st May 2026

Equity	₹920.16 Cr	96.83%
Others	₹30.15 Cr	3.17%

Top Holdings

All Holdings

Equity

Debt & Others

Name	Type	Amount	Holdings
Sun Pharmaceuticals Industries Ltd	Equity	₹118.04 Cr	12.42%
Apollo Hospitals Enterprise Ltd	Equity	₹69.45 Cr	7.31%
Torrent Pharmaceuticals Ltd	Equity	₹45.19 Cr	4.75%
J.B. Chemicals & Pharmaceuticals Ltd	Equity	₹44.97 Cr	4.73%
Aurobindo Pharma Ltd	Equity	₹41.54 Cr	4.37%
Ajanta Pharma Ltd	Equity	₹37.87 Cr	3.99%
Mankind Pharma Ltd	Equity	₹36.96 Cr	3.89%
Lupin Ltd	Equity	₹35.42 Cr	3.73%
Abbott India Ltd	Equity	₹34.73 Cr	3.65%
Fortis Healthcare Ltd	Equity	₹31.48 Cr	3.31%
Clearing Corporation Of India Limited	Cash - Repurchase Agreement	₹30.66 Cr	3.23%
Emcure Pharmaceuticals Ltd	Equity	₹30.15 Cr	3.17%
Cipla Ltd	Equity	₹28.31 Cr	2.98%
Shilpa Medicare Ltd	Equity	₹27.79 Cr	2.92%
Ipca Laboratories Ltd	Equity	₹23.1 Cr	2.43%
Sai Life Sciences Ltd	Equity	₹21.46 Cr	2.26%
Procter & Gamble Health Ltd	Equity	₹21.31 Cr	2.24%
Corona Remedies Ltd	Equity	₹19.61 Cr	2.06%
Alkem Laboratories Ltd	Equity	₹19.26 Cr	2.03%
Thyrocare Technologies Ltd	Equity	₹17.95 Cr	1.89%
Jupiter Life Line Hospitals Ltd	Equity	₹17.44 Cr	1.84%
Divi's Laboratories Ltd	Equity	₹17.33 Cr	1.82%
Metropolis Healthcare Ltd	Equity	₹14.92 Cr	1.57%
Sanofi Consumer Healthcare India Ltd	Equity	₹14.48 Cr	1.52%
Dr. Lal PathLabs Ltd	Equity	₹13.14 Cr	1.38%
Pfizer Ltd	Equity	₹12.9 Cr	1.36%
Dr Reddy's Laboratories Ltd	Equity	₹12.9 Cr	1.36%
Alembic Pharmaceuticals Ltd	Equity	₹11.85 Cr	1.25%
Biocon Ltd	Equity	₹11.64 Cr	1.23%
Gland Pharma Ltd	Equity	₹11.37 Cr	1.20%
Piramal Pharma Ltd	Equity	₹11.02 Cr	1.16%
Anthem Biosciences Ltd	Equity	₹10.77 Cr	1.13%
Vijaya Diagnostic Centre Ltd	Equity	₹10.23 Cr	1.08%
Medi Assist Healthcare Services Ltd	Equity	₹9.64 Cr	1.01%
Suraksha Diagnostic Ltd	Equity	₹9.57 Cr	1.01%
GlaxoSmithKline Pharmaceuticals Ltd	Equity	₹7.16 Cr	0.75%
Max Healthcare Institute Ltd Ordinary Shares	Equity	₹6.76 Cr	0.71%
Jubilant Pharmova Ltd	Equity	₹6.28 Cr	0.66%
Vinati Organics Ltd	Equity	₹6.14 Cr	0.65%
Net Receivables / (Payables)	Cash	₹-0.51 Cr	0.05%

Allocation By Market Cap (Equity)

Other Allocation

Equity Sector

Debt & Others

Sector	Amount	Holdings
Healthcare	₹914.02 Cr	96.18%
Basic Materials	₹6.14 Cr	0.65%

Risk & Performance Ratios

Fund Managers

Dhaval Shah

Since July 2019

Additional Scheme Detailsas of 31st May 2026

ISIN

INF209KB1O25

Expense Ratio

0.86%

Exit Load

1.00%

Fund Size

₹950 Cr

Age

6 years 11 months

Lumpsum Minimum

₹1,000

Fund Status

Open Ended Investment Company

Benchmark

BSE Healthcare TR INR

Investment Objective

To seek to generate long-term capital growth from an actively managed portfolio primarily of Equity and Equity Related Securities. Scheme shall invest in Indian equities,foreign equities and related instruments and debt securities.

Tax Treatment

Capital Gains Taxation:

Dividend Taxation:

Note: As per the Income Tax Budget 2024, mutual funds are subject to capital gains taxation, which includes surcharge and cess based on prevailing income tax rules and the investor’s income. Taxation applies only to realised gains, not notional gains. Please consult your tax advisors to determine the implications or consequences of your investments in such securities.

Similar Sector - Healthcare Funds

Fund name	Expense Ratio	Exit Load	Fund size	1Y
Groww BSE Hospitals ETF Very High Risk	0.9%	-	₹35.39 Cr	-
Mirae Asset Nifty 500 Healthcare ETF Very High Risk	0.1%	-	₹9.24 Cr	-
Bandhan Healthcare Fund Direct Growth Very High Risk	0.7%	0.0%	₹290.55 Cr	-
Bandhan Healthcare Fund Regular Growth Very High Risk	2.1%	0.0%	₹290.55 Cr	-
Baroda BNP Paribas Health and Wellness Fund Direct Growth Very High Risk	0.6%	1.0%	₹544.17 Cr	-
Baroda BNP Paribas Health and Wellness Fund Regular Growth Very High Risk	2.1%	1.0%	₹544.17 Cr	-
Bajaj Finserv Healthcare Fund Regular Growth Very High Risk	2.1%	1.0%	₹323.28 Cr	9.0%
Bajaj Finserv Healthcare Fund Direct Growth Very High Risk	0.7%	1.0%	₹323.28 Cr	10.9%
PGIM India Healthcare Fund Direct Growth Very High Risk	0.8%	0.0%	₹95.49 Cr	13.4%
PGIM India Healthcare Fund Regular Growth Very High Risk	2.5%	0.0%	₹92.44 Cr	11.5%
WhiteOak Capital Pharma and Healthcare Fund Regular Growth Very High Risk	2.6%	0.0%	₹602.93 Cr	14.5%
WhiteOak Capital Pharma and Healthcare Fund Direct Growth Very High Risk	0.9%	0.0%	₹602.93 Cr	16.5%
DSP Nifty Healthcare ETF Regular Growth Very High Risk	0.2%	-	₹14.94 Cr	9.1%
Kotak Healthcare Fund Direct Growth Very High Risk	0.8%	0.0%	₹560.17 Cr	17.0%
Kotak Healthcare Fund Regular Growth Very High Risk	2.5%	0.0%	₹560.17 Cr	15.1%
HDFC Pharma and Healthcare Fund Regular Growth Very High Risk	2.0%	1.0%	₹2362.44 Cr	18.1%
HDFC Pharma and Healthcare Fund Direct Growth Very High Risk	0.9%	1.0%	₹2362.44 Cr	19.5%
Nippon India Pharma Fund Direct Growth Very High Risk	0.8%	1.0%	₹8635.75 Cr	5.6%
ICICI Prudential Pharma Healthcare and Diagnostics (P.H.D) Fund Regular Growth Very High Risk	1.6%	1.0%	₹6453.52 Cr	5.4%
ICICI Prudential Pharma Healthcare and Diagnostics (P.H.D) Fund Direct Growth Very High Risk	0.9%	1.0%	₹6453.52 Cr	6.3%
DSP Healthcare Fund Direct Growth Very High Risk	0.5%	0.0%	₹3309.17 Cr	9.4%
DSP Healthcare Fund Regular Growth Very High Risk	1.7%	0.0%	₹3309.17 Cr	8.0%
LIC MF Healthcare Fund Direct Growth Very High Risk	1.1%	1.0%	₹88.96 Cr	8.8%
LIC MF Healthcare Fund Regular Growth Very High Risk	2.4%	1.0%	₹88.96 Cr	7.4%
quant Healthcare Fund Direct Growth Very High Risk	0.8%	1.0%	₹351.89 Cr	6.3%
quant Healthcare Fund Regular Growth Very High Risk	2.5%	1.0%	₹351.89 Cr	4.6%
UTI Healthcare Fund Direct Growth Very High Risk	1.4%	1.0%	₹1216.85 Cr	11.0%
SBI Healthcare Opportunities Fund Direct Growth Very High Risk	0.9%	0.0%	₹4565.95 Cr	11.2%
Tata India Pharma & Healthcare Fund Regular Growth Very High Risk	1.8%	0.0%	₹1386.99 Cr	4.8%
Tata India Pharma & Healthcare Fund Direct Growth Very High Risk	0.7%	0.0%	₹1386.99 Cr	6.3%
ICICI Prudential Nifty Healthcare ETF Very High Risk	0.1%	-	₹202.94 Cr	9.2%
SBI Healthcare Opportunities Fund Regular Growth Very High Risk	1.9%	0.0%	₹4565.95 Cr	10.0%
Nippon India Pharma Fund Regular Growth Very High Risk	1.5%	1.0%	₹8635.75 Cr	4.7%
UTI Healthcare Fund Regular Growth Very High Risk	2.3%	1.0%	₹1216.85 Cr	9.9%
Axis NIFTY Healthcare ETF Very High Risk	0.4%	-	₹22.75 Cr	8.9%
Nippon India Nifty Pharma ETF Very High Risk	0.2%	-	₹1570.17 Cr	11.3%
Mirae Asset Healthcare Fund Regular Growth Very High Risk	1.7%	1.0%	₹2939.23 Cr	11.7%
Mirae Asset Healthcare Fund Direct Growth Very High Risk	0.4%	1.0%	₹2939.23 Cr	13.3%
ITI Pharma and Healthcare Fund Regular Growth Very High Risk	4.8%	0.0%	₹229.56 Cr	2.4%
ITI Pharma and Healthcare Fund Direct Growth Very High Risk	3.1%	0.0%	₹229.56 Cr	4.3%
Aditya Birla Sun Life Nifty Healthcare ETF Very High Risk	0.2%	-	₹74.45 Cr	9.1%
Aditya Birla Sun Life Pharma & Healthcare Fund Regular Growth Very High Risk	2.0%	1.0%	₹900.87 Cr	10.6%
Aditya Birla Sun Life Pharma & Healthcare Fund Direct Growth Very High Risk	0.9%	1.0%	₹950.31 Cr	12.1%
Motilal Oswal S&P BSE Healthcare ETF Very High Risk	0.3%	-	₹41.85 Cr	8.2%

About the AMC

Aditya Birla SL Mutual Fund

+91 22 43568000

https://mutualfund.adityabirlacapital.com/

Total AUM

₹4,31,670 Cr

Address

One World Centre, Tower 1, 17th Floor, Mumbai, 400 013

Other Funds by Aditya Birla SL Mutual Fund

Fund name	Expense Ratio	Exit Load	Fund size	1Y
Apex Hybrid Long-Short Fund Direct Growth Low to Moderate Risk	-	0.0%	₹63.25 Cr	-
Aditya Birla Sun Life BSE 500 Quality 50 Index Fund Direct Growth Very High Risk	0.2%	0.0%	₹77.33 Cr	-
Aditya Birla Sun Life BSE 500 Momentum 50 Index Fund Direct Growth Very High Risk	0.3%	0.0%	₹70.28 Cr	-
Aditya Birla Sun Life CRISIL-IBX Financial Services 9-12 Months Debt Index Fund Direct Growth Low to Moderate Risk	0.1%	0.0%	₹1538.08 Cr	5.9%
Aditya Birla Sun Life CRISIL-IBX Financial Services 3 to 6 Months Debt Index Fund Direct Growth Low to Moderate Risk	0.1%	0.0%	₹2842.45 Cr	6.6%
Aditya Birla Sun Life Conglomerate Fund Direct Growth Very High Risk	0.6%	0.0%	₹1624.31 Cr	0.2%
Aditya Birla Sun Life BSE India Infrastructure Index Fund Direct Growth Very High Risk	0.4%	0.0%	₹33.87 Cr	-0.2%
Aditya Birla Sun Life CRISIL-IBX AAA Financial Services Index Sep 2027 Fund Direct Growth Moderate Risk	0.1%	0.0%	₹10.24 Cr	6.2%
Aditya Birla Sun Life CRISIL-IBX AAA NBFC-HFC Index Dec 2025 Fund Direct Growth Low to Moderate Risk	0.1%	0.0%	₹276.54 Cr	7.6%
Aditya Birla Sun Life CRISIL-IBX AAA NBFC-HFC Index Sep 2026 Fund Direct Growth Moderate Risk	0.1%	0.0%	₹115.12 Cr	6.8%
Aditya Birla Sun Life Nifty India Defence Index Fund Direct Growth Very High Risk	0.3%	0.0%	₹1165.95 Cr	3.8%
Aditya Birla Sun Life Quant Fund Direct Growth Very High Risk	0.6%	0.0%	₹2045.05 Cr	6.5%
Aditya Birla Sun Life Crisil IBX Gilt June 2027 Index Fund Direct Growth Low to Moderate Risk	0.3%	0.0%	₹12.45 Cr	5.4%
Aditya Birla Sun Life Fixed Maturity Plan-Series UU (98 days) Direct Growth Moderately High risk	-	0.0%	-	-
Aditya BSL Fixed Term Plan Series UT (91 days) Direct Growth Low to Moderate Risk	-	0.0%	-	-
Aditya Birla Sun Life Fixed Maturity Plan-Series US (100 days) Direct Growth Moderate Risk	-	0.0%	-	-
Aditya Birla Sun Life Fixed Maturity Plan-Series UR (85 days) Direct Growth Low to Moderate Risk	-	0.0%	₹104.95 Cr	-
Aditya Birla Sun Life Crisil IBX Gilt April 2033 Index Fund Direct Growth Moderate Risk	0.2%	0.0%	₹26.80 Cr	4.1%
Aditya Birla Sun Life Fixed Maturity Plan-Series UQ (92 days) Direct Growth Moderate Risk	-	0.0%	-	-
Aditya Birla Sun Life Transportation and Logistics Fund Direct Growth Very High Risk	0.7%	1.0%	₹1491.90 Cr	12.1%
Aditya Birla Sun Life US Treasury 1-3 year Bond ETFs Fund of Funds Direct Growth Very High Risk	0.2%	0.0%	₹72.18 Cr	15.7%
Aditya Birla Sun Life US Treasury 3-10 Year Bond ETFs Fund of Funds Direct Growth Very High Risk	0.2%	0.0%	₹140.97 Cr	15.7%
Aditya Birla Sun Life Fixed Term Plan - Series SY (1259 days) Direct Growth Low to Moderate Risk	-	-	-	-
Aditya Birla Sun Life Fixed Term Plan Series SP Direct Growth Low to Moderate Risk	-	0.0%	-	-
Aditya Birla Sun Life Fixed Term Plan - Series TV (1169 Days) Direct Growth Moderate Risk	-	0.0%	-	-
Aditya BSL Fixed Term Plan Series SC(1170 days) Direct Growth Low to Moderate Risk	-	0.0%	-	-
Aditya BSL Fixed Term Plan Series SM Direct Growth Low to Moderate Risk	-	0.0%	-	-
Aditya Birla Sun Life Fixed Term Plan Series TN Direct Growth Low to Moderate Risk	-	-	-	-
Aditya Birla Sun Life Fixed Term Plan - Series TL (1839 days) Direct Growth Moderate Risk	-	0.0%	-	-
Aditya BSL Fixed Term Plan Series RM (91 days) Direct Growth Low to Moderate Risk	-	0.0%	-	-
Aditya BSL Fixed Term Plan Series SE(1163 days) Direct Growth Low to Moderate Risk	-	0.0%	-	-
Aditya Birla Sun Life Fixed Term Plan - Series TM (1842 days) Direct Growth Moderate Risk	-	-	-	-
Aditya Birla Sun Life Fixed Term Plan - Series TP (1923 Days) Direct Growth Moderate Risk	-	0.0%	-	-
Aditya Birla Sun Life Fixed Term Plan - Series TK (1833 days) Direct Growth Moderate Risk	-	0.0%	-	-
Aditya BSL Fixed Term Plan Series RG(1283 days) Direct Growth Low to Moderate Risk	-	0.0%	-	-
Aditya BSL Fixed Term Plan Series SD(1168 days) Direct Growth Low to Moderate Risk	-	0.0%	-	-
Aditya Birla Sun Life Fixed Term Plan Series TO (1214 days) Direct Growth Moderate Risk	-	0.0%	-	-
Aditya Birla Sun Life Fixed Term Plan - Series TE (1095 days) Direct Growth Moderate Risk	-	0.0%	-	-
Aditya Birla Sun Life Fixed Term Plan - Series TF (1098 days) Direct Growth Moderate Risk	-	0.0%	-	-
Aditya BSL Fixed Term Plan SeriesSH (1146 days) Direct Growth Low to Moderate Risk	-	0.0%	-	-
Aditya Birla Sun Life Interval Income Fund Quarterly Series I Direct Growth Low Risk	-	0.0%	₹28.97 Cr	6.1%
Aditya BSL Fixed Term Plan Series RZ(1187 days) Direct Growth Low to Moderate Risk	-	0.0%	-	-
Aditya BSL Fixed Term Plan Series SB(1174 days) Direct Growth Low to Moderate Risk	-	0.0%	-	-
Aditya Birla Sun Life Fixed Term Plan Series TC (1119 days) Direct Growth Moderate Risk	-	0.0%	-	-
Aditya Birla Sun Life Fixed Term Plan Series UB (1224 Days) Direct Growth Low Risk	-	0.0%	₹24.33 Cr	6.0%
Aditya Birla Sun Life Fixed Term Plan - Series TJ (1838 days) Direct Growth Low Risk	-	0.0%	₹27.49 Cr	5.8%
Aditya Birla Sun Life Fixed Term Plan Series TI (1837 days) Direct Growth Low Risk	-	0.0%	₹333.51 Cr	5.7%
Aditya Birla Sun Life Fixed Term Plan - Series TG (1099 days) Direct Growth Moderate Risk	-	0.0%	-	-
Aditya Birla Sun Life Fixed Term Plan Series TW (167 days) Direct Growth Low to Moderate Risk	-	0.0%	-	-
Aditya Birla Sun Life Fixed Term Plan Series UC (95 days) Direct Growth Low to Moderate Risk	-	-	-	-

Risk Level

Your principal amount will be at Very High Risk

Take control of your wealth

Track and Analyse all your investments with Dezerv

Rated ★ 4.3+ on

Still got questions?
We're here to help.

What is the current NAV of Aditya Birla Sun Life Pharma & Healthcare Fund Direct Growth?

The NAV of Aditya Birla Sun Life Pharma & Healthcare Fund Direct Growth, as of 12-Jun-2026, is ₹37.37.

What are the returns of Aditya Birla Sun Life Pharma & Healthcare Fund Direct Growth?

The fund has generated 12.09% over the last 1 year and 25.34% over the last 3 years. However, this does not guarantee that the fund will perform similarly in the future.

What is the portfolio composition of Aditya Birla Sun Life Pharma & Healthcare Fund Direct Growth?

The fund's allocation of assets is distributed as 96.83% in equities, 0.00% in bonds, and 3.17% in cash and cash equivalents.

Who manages the Aditya Birla Sun Life Pharma & Healthcare Fund Direct Growth?

The fund managers responsible for Aditya Birla Sun Life Pharma & Healthcare Fund Direct Growth are:-

Dhaval Shah

Disclaimer: Mutual Fund investments are subject to market risks, read all scheme-related documents carefully. The NAVs of the schemes may go up or down depending upon the factors and forces affecting the securities market including the fluctuations in the interest rates. The past performance of the mutual funds is not necessarily indicative of the future performance of the schemes. Investors are requested to review the prospectus carefully and obtain expert professional advice with regard to specific legal, tax and financial implications of the investment/participation in the scheme.

;

©2021-2026 Dezerv. All Rights Reserved

Dezerv Investments Pvt. Ltd. is a Portfolio Manager with SEBI Registration no. INP000007377, a member of BSE with SEBI Stock Broker Registration no. INZ000303136, and an Investment Manager to Category - I AIF-VCF-Angel Fund with SEBI Registration no. IN/AIF1/22-23/1066.

Mutual Fund distribution services are offered through Dezerv Distribution Services Pvt Limited, a wholly owned subsidiary with AMFI Registration No.: ARN -248439. **Mutual fund investments are subject to market risks, read all scheme related documents carefully.** Terms and conditions of the website are applicable. Privacy policy of the website is applicable.

Aditya Birla Sun Life Pharma & Healthcare Fund Direct Growth

Fund Overview